SUBSCRIBE
SUBSCRIBE
Tyler Patchen

Tyler Patchen

Freelance Writer

Tyler is a journalist with over six years of experience in the world of business journalism. He started his career with the Birmingham Business Journal in Birmingham, Alabama writing about health care, technology, sports business and education. He previously worked as a reporter for Endpoints News and for BioSpace, covering biopharma business and manufacturing. Tyler currently lives in Birmingham, Alabama and holds interests in reading, golf and is also a passionate sports fan. You can reach him at tpatchen94@gmail.com.

Pictured: J&J's office in Madrid, Spain
Drug Development
J&J Inks $1.25B Deal to Buy Rights to Atopic Dermatitis Candidate from Numab
Johnson & Johnson’s deal for Numab Therapeutics’ bispecific antibody NM26, slated to enter Phase II studies, comes on the heels of J&J’s $850 million Proteologix bispecific antibody acquisition.
May 28, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: Businessmen shaking hands after closing a deal
Deals
Asahi Kasei Offers $1.1B for Swedish Pharma Calliditas Therapeutics
The potential purchase by the Japanese conglomerate could secure access to Calliditas’ IgA nephropathy therapy Tarpeyo, which won the FDA’s full approval in December 2023.
May 28, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: Eli Lilly's headquarters in Indianapolis
Drug Development
Lilly Invests Another $5.3B in Indiana Plant to Boost Tirzepatide Manufacturing
Amid shortages of its Mounjaro and Zepbound blockbuster drugs, Eli Lilly on Friday said it is investing an additional $5.3 billion in its production site in Lebanon, Indiana, to boost output of their active ingredient.
May 24, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: Injection pens meant for weight-loss medications
Drug Development
Zealand Touts Phase I Results for GLP-1, GLP-2 Candidate Despite Modest Weight Loss
Aiming to compete in the lucrative weight-loss drug market, Zealand Pharma on Thursday posted topline results showing its dapiglutide led to only a slight weight reduction in low doses.
May 24, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: Two business professionals in suits shaking hands
Deals
Orna Buys Competing RNA Biotech ReNAgade After Series A Financing
Orna Therapeutics announced Thursday it is acquiring ReNAgade Therapeutics, which launched in May 2023 with $300 million in Series A financing and is on BioSpace’s NextGen Class of 2024 startups to watch this year.
May 23, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: Bayer and BMS buildings
Business
Big Pharma Layoffs by the Thousands: Are Bayer and BMS Harbingers of More?
Patent cliffs and other factors may lead other large drugmakers to embrace similar cost-cutting measures, experts tell BioSpace.
May 22, 2024
 · 
4 min read
 · 
Tyler Patchen
Pictured: Young man hugging his belly suffering from stomach pain while lying in bad at home
Drug Development
AltruBio Raises $225M in Series B to Advance Ulcerative Colitis Candidate
Formerly known as AbGenomics Holding, AltruBio on Tuesday said it will use the funds to push its ulcerative colitis asset into a Phase IIb trial with an anticipated readout in 2026.
May 21, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: Gilead corporate headquarters in Silicon Valley
Drug Development
Gilead Touts Phase III Results for Liver Disease Drug Ahead of PDUFA Date
Seladelpar, which Gilead acquired when it bought CymaBay in February for $4.3 billion, showed positive results for reducing pruritus in primary biliary cholangitis patients and reducing inflammation.
May 20, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: Bayer's office in New Jersey
Drug Development
Bayer Touts Phase III Results for Menopause Symptom Drug
Bayer on Thursday provided additional data on late-stage studies of its rival drug to Astellas’ Veozah, which met all primary endpoints.
May 17, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: Exterior of Eli Lilly's facility in Boston, Mass.
Drug Development
Lilly’s Weekly Insulin Scores Late-Stage Win as Race With Novo Heats Up
Eli Lilly’s efsitora alfa, which is meant to be taken weekly instead of multiple times a day, demonstrated non-inferior A1C reduction in a Phase III trial compared to Novo Nordisk’s daily insulin.
May 16, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: 3D illustration of a human antibody binding to human cell receptors
Drug Development
Attovia Secures $105M Series B to Expand I&I Pipeline of Bispecific Antibodies
The Bay Area–based biotech plans to use the funds to advance two lead programs, one to treat atopic dermatitis and another for immune-mediated diseases.
May 9, 2024
 · 
1 min read
 · 
Tyler Patchen
Pictured: The exterior of a Teva facility in Whitchurch-Stouffville, Ontario, Canada
Drug Development
Teva Misses Q1 Profit Estimates, Touts Phase III Schizophrenia Win
While Teva missed Wall Street expectations in the first quarter of 2024, it reported Wednesday a 5% increase in Q1 revenues while reporting that the company’s schizophrenia candidate scored a late-stage trial victory
May 8, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: Collage of Sarepta Therapeutics, DNA, and an IV bag
FDA
Sarepta Seeks Label Expansion, Bigger Market for DMD Gene Therapy
As Sarepta Therapeutics moves closer to full approval and an expanded label for its gene therapy, some experts push back on clinical efficacy and cost while others note the hope it provides patients with Duchenne muscular dystrophy.
May 7, 2024
 · 
4 min read
 · 
Tyler Patchen
Pictured: Businessmen shaking hands after closing a deal
Business
Chiesi Inks Potential $486M Deal with Gossamer Bio for Blood Pressure Treatment
The Italian pharma will gain access to Gossamer Bio’s candidate seralutinib, which reached its primary endpoint in a Phase II pulmonary arterial hypertension trial in 2022 and started a Phase III study last year.
May 6, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: Mother covering her face, experiencing depression symptoms
Drug Development
Novo-Backed Reunion Raises $103M Series A Financing for Psychedelic Trial
The New Jersey-based biopharma will use the funds to support a Phase II study of its serotonergic psychedelic drug candidate in postpartum depression.
May 3, 2024
 · 
2 min read
 · 
Tyler Patchen
Load More